The drug landscape in the nation is increasingly characterized by a appearance toward market concentration, with a handful of large companies wielding significant control. These industry giants, often bolstered by established distribution networks and robust brand recognition, present a complex picture for competition and affordable healthcare. Whi

The Indian pharmaceutical industry, known for its affordable and accessible medicines, faces rising concerns about monopolies. A few dominant firms control a significant percentage of the market, potentially limiting competition and driving up prices for consumers. This issue raises questions about the long-term impact on patient access to afforda